<VariationArchive VariationID="216135" VariationName="NM_138694.4(PKHD1):c.7560dup (p.Ala2521fs)" VariationType="Duplication" Accession="VCV000216135" Version="8" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-06-23" DateCreated="2015-10-11" MostRecentSubmission="2024-06-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="212525" VariationID="216135">
      <GeneList>
        <Gene Symbol="PKHD1" FullName="PKHD1 ciliary IPT domain containing fibrocystin/polyductin" GeneID="5314" HGNC_ID="HGNC:9016" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>6p12.3-12.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="51615299" stop="52087615" display_start="51615299" display_stop="52087615" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="51480144" stop="51952422" display_start="51480144" display_stop="51952422" Strand="-" />
          </Location>
          <OMIM>606702</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_138694.4(PKHD1):c.7560dup (p.Ala2521fs)</Name>
      <CanonicalSPDI>NC_000006.12:51868035:A:AA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>6p12.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="51868035" stop="51868036" display_start="51868035" display_stop="51868036" variantLength="1" positionVCF="51868035" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="51732833" stop="51732834" display_start="51732833" display_stop="51732834" variantLength="1" positionVCF="51732833" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
      </Location>
      <ProteinChange>A2521fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000006.11" sequenceAccession="NC_000006" sequenceVersion="11" change="g.51732834dup" Assembly="GRCh37">
            <Expression>NC_000006.11:g.51732834dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000006.12" sequenceAccession="NC_000006" sequenceVersion="12" change="g.51868036dup" Assembly="GRCh38">
            <Expression>NC_000006.12:g.51868036dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008753.1" sequenceAccession="NG_008753" sequenceVersion="1" change="g.224590dup">
            <Expression>NG_008753.1:g.224590dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_138694.4" sequenceAccession="NM_138694" sequenceVersion="4" change="c.7560dup" MANESelect="true">
            <Expression>NM_138694.4:c.7560dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_619639.3" sequenceAccession="NP_619639" sequenceVersion="3" change="p.Ala2521fs">
            <Expression>NP_619639.3:p.Ala2521fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_170724.3" sequenceAccession="NM_170724" sequenceVersion="3" change="c.7560dup">
            <Expression>NM_170724.3:c.7560dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_733842.2" sequenceAccession="NP_733842" sequenceVersion="2" change="p.Ala2521fs">
            <Expression>NP_733842.2:p.Ala2521fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA339528" DB="ClinGen" />
        <XRef Type="rs" ID="863224528" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_138694.4(PKHD1):c.7560dup (p.Ala2521fs) AND Autosomal recessive polycystic kidney disease" Accession="RCV000200756" Version="7">
        <ClassifiedConditionList TraitSetID="1127">
          <ClassifiedCondition DB="MedGen" ID="C0085548">Autosomal recessive polycystic kidney disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2015-02-09" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_138694.4(PKHD1):c.7560dup (p.Ala2521fs) AND Polycystic kidney disease 4" Accession="RCV004567411" Version="1">
        <ClassifiedConditionList TraitSetID="57093">
          <ClassifiedCondition DB="MedGen" ID="C4540575">Polycystic kidney disease 4</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-02-10" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-02-10" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2015-10-11" MostRecentSubmission="2024-06-17">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <DescriptionHistory Dated="2024-06-13">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="57093" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="54596" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Polycystic kidney disease 4</ElementValue>
                <XRef ID="MONDO:0033004" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PKD3</ElementValue>
                <XRef Type="MIM" ID="263200" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POLYCYSTIC KIDNEY DISEASE 4 WITH OR WITHOUT POLYCYSTIC LIVER DISEASE</ElementValue>
                <XRef Type="MIM" ID="263200" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">ARPKD</ElementValue>
                <XRef Type="MIM" ID="263200" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">PKD4</ElementValue>
                <XRef Type="MIM" ID="263200" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6168" />
                <XRef ID="6168" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Autosomal recessive polycystic kidney disease (ARPKD) belongs to a group of congenital hepatorenal fibrocystic syndromes and is a cause of significant renal and liver-related morbidity and mortality in children. The majority of individuals with ARPKD present in the neonatal period with enlarged echogenic kidneys. Renal disease is characterized by nephromegaly, hypertension, and varying degrees of renal dysfunction. More than 50% of affected individuals with ARPKD progress to end-stage renal disease (ESRD) within the first decade of life; ESRD may require kidney transplantation. Pulmonary hypoplasia resulting from oligohydramnios occurs in a number of affected infants. Approximately 30% of these infants die in the neonatal period or within the first year of life from respiratory insufficiency or superimposed pulmonary infections. With neonatal respiratory support and renal replacement therapies, the long-term survival of these infants has improved to greater than 80%. As advances in renal replacement therapy and kidney transplantation improve long-term survival, it is likely that clinical hepatobiliary disease will become a major feature of the natural history of ARPKD. In addition, a subset of individuals with this disorder are identified with hepatosplenomegaly; the renal disease is often mild and may be discovered incidentally during imaging studies of the abdomen. Approximately 50% of infants will have clinical evidence of liver involvement at diagnosis although histologic hepatic fibrosis is invariably present at birth. This can lead to progressive portal hypertension with resulting esophageal or gastric varices, enlarged hemorrhoids, splenomegaly, hypersplenism, protein-losing enteropathy, and gastrointestinal bleeding. Other hepatic findings include nonobstructed dilatation of the intrahepatic bile ducts (Caroli syndrome) and dilatation of the common bile duct, which may lead to recurrent or persistent bacterial ascending cholangitis due to dilated bile ducts and stagnant bile flow. An increasing number of affected individuals surviving the neonatal period will eventually require portosystemic shunting or liver transplantation for complications of portal hypertension or cholangitis. The classic neonatal presentation of ARPKD notwithstanding, there is significant variability in age and presenting clinical symptoms related to the relative degree of renal and biliary abnormalities.</Attribute>
                <XRef ID="NBK1326" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301501</ID>
                <ID Source="BookShelf">NBK1326</ID>
              </Citation>
              <XRef ID="C4540575" DB="MedGen" />
              <XRef ID="MONDO:0033004" DB="MONDO" />
              <XRef Type="MIM" ID="263200" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1127" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3987" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Polycystic kidney disease, infantile type</ElementValue>
                <XRef ID="Autosomal+Recessive+Polycystic+Kidney+Disease/691" DB="Genetic Alliance" />
                <XRef ID="28770003" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">AR polycystic kidney disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">POLYCYSTIC KIDNEY AND HEPATIC DISEASE 1</ElementValue>
                <XRef Type="MIM" ID="263200" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POLYCYSTIC KIDNEY DISEASE, INFANTILE, TYPE I</ElementValue>
                <XRef Type="MIM" ID="263200" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Autosomal recessive polycystic kidney disease</ElementValue>
                <XRef ID="MONDO:0009889" DB="MONDO" />
                <XRef ID="731" DB="Orphanet" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PKHD1</ElementValue>
                <XRef Type="MIM" ID="263200" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">ARPKD</ElementValue>
                <XRef ID="MONDO:0009889" DB="MONDO" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PKD4</ElementValue>
                <XRef ID="GTR000531706" DB="Genetic Testing Registry (GTR)" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8378" />
                <XRef ID="8378" DB="Office of Rare Diseases" />
                <XRef ID="8378" DB="Orphanet" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Autosomal recessive polycystic kidney disease (ARPKD) belongs to a group of congenital hepatorenal fibrocystic syndromes and is a cause of significant renal and liver-related morbidity and mortality in children. The majority of individuals with ARPKD present in the neonatal period with enlarged echogenic kidneys. Renal disease is characterized by nephromegaly, hypertension, and varying degrees of renal dysfunction. More than 50% of affected individuals with ARPKD progress to end-stage renal disease (ESRD) within the first decade of life; ESRD may require kidney transplantation. Pulmonary hypoplasia resulting from oligohydramnios occurs in a number of affected infants. Approximately 30% of these infants die in the neonatal period or within the first year of life from respiratory insufficiency or superimposed pulmonary infections. With neonatal respiratory support and renal replacement therapies, the long-term survival of these infants has improved to greater than 80%. As advances in renal replacement therapy and kidney transplantation improve long-term survival, it is likely that clinical hepatobiliary disease will become a major feature of the natural history of ARPKD. In addition, a subset of individuals with this disorder are identified with hepatosplenomegaly; the renal disease is often mild and may be discovered incidentally during imaging studies of the abdomen. Approximately 50% of infants will have clinical evidence of liver involvement at diagnosis although histologic hepatic fibrosis is invariably present at birth. This can lead to progressive portal hypertension with resulting esophageal or gastric varices, enlarged hemorrhoids, splenomegaly, hypersplenism, protein-losing enteropathy, and gastrointestinal bleeding. Other hepatic findings include nonobstructed dilatation of the intrahepatic bile ducts (Caroli syndrome) and dilatation of the common bile duct, which may lead to recurrent or persistent bacterial ascending cholangitis due to dilated bile ducts and stagnant bile flow. An increasing number of affected individuals surviving the neonatal period will eventually require portosystemic shunting or liver transplantation for complications of portal hypertension or cholangitis. The classic neonatal presentation of ARPKD notwithstanding, there is significant variability in age and presenting clinical symptoms related to the relative degree of renal and biliary abnormalities.</Attribute>
                <XRef ID="NBK1326" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301501</ID>
                <ID Source="BookShelf">NBK1326</ID>
              </Citation>
              <Citation Type="general" Abbrev="Guay-Woodford et al., 2014">
                <ID Source="PubMed">25015577</ID>
              </Citation>
              <XRef ID="731" DB="Orphanet" />
              <XRef ID="8378" DB="Orphanet" />
              <XRef ID="C0085548" DB="MedGen" />
              <XRef ID="D017044" DB="MeSH" />
              <XRef ID="MONDO:0009889" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="469064" SubmissionDate="2024-02-07" DateLastUpdated="2024-02-28" DateCreated="2015-10-11">
        <ClinVarSubmissionID localKey="1175932|MedGen:C0085548" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000253970" DateUpdated="2024-02-28" DateCreated="2015-10-11" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-02-09">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>For these reasons, this variant has been classified as Pathogenic. While this particular variant has not been reported in the literature, truncating variants in PKHD1 are known to be pathogenic (PMID:¬†1569842). This sequence change inserts 1 nucleotide in exon 48 of the PKHD1 mRNA (c.7560dupT), causing a frameshift at codon 2521. This creates a premature translational stop signal (p.Ala2521Cysfs*63) and is expected to result in an absent or disrupted protein product.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PKHD1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000006.11:g.51732833_51732834insA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0085548" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2015September</SubmissionName>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14200269</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9813049" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2024-06-17">
        <ClinVarSubmissionID localKey="NM_138694.4:c.7560dup|OMIM:263200" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV005056322" DateUpdated="2024-06-17" DateCreated="2024-06-17" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_138694.4:c.7560dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="263200" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="469064" TraitType="Disease" MappingType="XRef" MappingValue="C0085548" MappingRef="MedGen">
        <MedGen CUI="C0085548" Name="Autosomal recessive polycystic kidney disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9813049" TraitType="Disease" MappingType="XRef" MappingValue="263200" MappingRef="OMIM">
        <MedGen CUI="C4540575" Name="Polycystic kidney disease 4" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

